Navigation Links
Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
Date:9/25/2007

- Data Sufficient to Advance Product to Pivotal Phase -

WALTHAM, Mass., Sept. 25 /PRNewswire-FirstCall/ -- Arbios Systems, Inc. (OTC Bulletin Board: ABOS), today provided its clinical trial strategy for the SEPET(TM) Liver Assist Device including information regarding a pre-pivotal phase meeting with the US Food and Drug Administration (FDA). In a meeting held between Arbios and the FDA's Office for Device Evaluation and Research (ODE), the FDA indicated that, pending receipt of a final report, SEPET(TM) has met the required feasibility trial objectives and Arbios may advance its clinical development program to the pivotal phase. In response to the presentation of a pivotal trial design, the FDA provided the Company with comment and further indicated that a single pivotal study may be acceptable to the FDA, subject to a submission of a full clinical protocol to include additional information required in an Investigational Device Exemption (IDE) application. Arbios intends to file this information for review in the coming weeks, as a potential final step toward FDA authorization of a pivotal clinical trial for SEPET(TM).

"We are pleased with the discussion at our recent meeting with the FDA regarding our SEPET(TM) Liver Assist Device," commented Shawn Cain, Interim President and Chief Executive Officer of Arbios. "Following the results of our feasibility clinical trial, the FDA review group said that SEPET(TM) could advance into a multicenter pivotal clinical trial. We appear to be on track for near-term initiation of a pivotal registration trial of SEPET(TM) in the US."

We expect the proposed pivotal clinical trial would enroll 80 patients in the principal randomized, controlled phase of the study, targeted to achieve the primary endpoint of the trial, which is a clinically significant reduction in hepatic encephalopathy. Patients receiving SEPET(TM) treatment plus standard medical care would be compared to control patients receiving
'/>"/>

SOURCE Arbios Systems, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
2. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
3. XTL Provides Update on Phase I Clinical Trial of XTL-2125
4. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
5. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
6. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
7. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
8. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
9. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
10. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
11. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2008)...icroRNAs as Potential Biomarkers -- for Lung Cance... Patients With Cancer of Unknown Primary ...ely Identify Cancer Types With High Sensitivity an... and Treatment of Cancer Results of microRNA Sign... Accuracy Exceeding 90% and Specificity of 99...
(Date:5/15/2008)...ODCLIFF LAKE, N.J., May 15 /- Eisai C...esults from 16 clinical data abstracts about,compo...ortfolio and,preclinical oncology research have be...eting of the American Society of Clinical Oncology...ne 3, 2008., A wide variety of abstracts on Eisai...
(Date:5/15/2008)...e II Data Presented at ASCO Showed Acceptable Tole...f Grade 3 and 4 Neuropathy, WOODCLIFF LAKE, N.J.,...herapeutic agent eribulin mesylate (E7389) demonst...of women with locally advanced or metastatic,breas...hase II clinical,trial. The study also suggests th...
(Date:5/15/2008)...IDGEWATER, N.J., May 15 /- ...nced today that findings from the,landmark ATHENA ...therapy,for the treatment of patients with atrial ... of cardiovascular hospitalizations or death from ...00000002), meeting the study,primary endpoint. The...
Breaking Medicine Technology:Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 3Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 4Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 5Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 6Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 2Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 3Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 4Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 5Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 6Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 7Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 8Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 3Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 2Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 3Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 4Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 5Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 6Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 7Federal Government Receives Failing Grades on Tobacco Control in Annual American Lung Association Report 9355 1Federal Government Receives Failing Grades on Tobacco Control in Annual American Lung Association Report 9355 2Federal Government Receives Failing Grades on Tobacco Control in Annual American Lung Association Report 9355 3Federal Government Receives Failing Grades on Tobacco Control in Annual American Lung Association Report 9355 4NIST develops test method for key micromechanical property 2534 1NIST develops test method for key micromechanical property 2534 2University of Maryland Baltimore BioPark Signs Gliknik Inc as First Tenant in Its BioInnovation Center in Building Two 2532 1University of Maryland Baltimore BioPark Signs Gliknik Inc as First Tenant in Its BioInnovation Center in Building Two 2532 2FDA Asserts New Policy to Restrict Womens Access to Bioidentical Hormones 9348 1FDA Asserts New Policy to Restrict Womens Access to Bioidentical Hormones 9348 2
(Date:5/16/2008)...quires Rival JoAnne,s Bed & Back; Merger Sets Up H...wned Back Retail Chain, LORTON, Va., May 16 /PRNe...hose focus on home and workplace back wellness cre...stantial assets of its rival,JoAnne,s Bed & Back....laimed 2007 revenues of $40million. JoAnne,s 16 mi...
(Date:5/16/2008)...cause increase in serum parathyroid hormone readin...hDay News) -- Low levels of vitamin D and high lev...s may increase the risk of depression in older adu...udy, published in the May issue of Archives of Ge...y researchers that vitamin D, depression and other...
(Date:5/16/2008)...ign to Emphasize the Importance of Oral and Overal... National dental insurer United,Concordia Dental i...n,between Oral Health America and the British Dent...oral health to overall health. Beginning May 18,t... for the first time,making it the largest indepen...
(Date:5/16/2008)...n international, multicenter Phase III clinical tr...py everolimus (RAD001) significantly delays cancer...ncer whose disease had worsened on other treatment...ending physician at Memorial Sloan-Kettering Cance... May 31 at the annual meeting of the American Soci...
Breaking Medicine News(10 mins):Health News:The Back Wars Come to a Close 2Health News:Low Vitamin D Tied to Depression in Older Adults 2Health News:United Concordia Dental Celebrates National Smile Month 2Health News:Drug fends off kidney cancer progression 2
...estyle can contribute heavily to high blood pressu...evealed that distressing can happen through transc...ention and control of these diseases. For populati...e the extreme stressful life, interventions in the...
...lood clots, the combination of Clopidogrel and asp...sults were declared after 107 participants across ...ation medication or only aspirin. Each of the part...ke or transient ischemic attack (TIA). All the pat...
...regnant mothers is quite a common procedure. A new...ely// administered to pregnant mothers as a precau... is an inactivated vaccine containing killed virus...s may be given to anybody older than 6 months, inc...
... an herb, is often used for treatment of menopausa...on with the chemotherapy taken for breast cancer t...ol of Medicine in a research report have said that...tion taken by breast cancer patients may alter the...
Other Medicine News:
All USIOL lenses are manufactured using the highest quality materials and processes. Perspex CQ UV PMMA material is used in the multi-piece and single piece lenses. Unioptic lens models are available
Optical implants for the replacement of the human crystalline lens in the visual correction of aphakia.
1% Sodium Hyaluronate, 10mg/mL, sterile opthalmic injection
...ptimum molecular weight and viscosity, so that it ...cts the delicate structures of the eye. , ,Ray...and pseudoplasticity to satisfy all the requiremen...phthalmic viscoelastic device. , ,Combine thes...
Medicine Products: